BioCentury | Dec 14, 2018
Financial News

Moderna raises $604M in record IPO, loses $1.4B in trading debut

...held a 19.5% pre-IPO stake in the company. CEO Stéphane Bancel held 10%. Moderna knocks Talecris Biotherapeutics Inc....
...had multiple marketed therapies at the time of its listing. Grifols S.A. (Madrid:GRF; NASDAQ:GRFS) acquired Talecris...
BioCentury | Dec 7, 2018
Financial News

Moderna sets IPO record with upsized $604M offering

...held a 19.5% pre-IPO stake in the company. CEO Stéphane Bancel held 10%. Moderna knocks Talecris Biotherapeutics Inc....
...had multiple marketed therapies at the time of its listing. Grifols S.A. (Madrid:GRF; NASDAQ:GRFS) acquired Talecris...
BioCentury | Nov 30, 2018
Financial News

Moderna proposes terms for record IPO

...see "Maintaining Moderna" ). The largest biotech IPO on NASDAQ belongs to plasma protein company Talecris Biotherapeutics Inc....
BioCentury | Nov 28, 2018
Financial News

Moderna proposes terms for record IPO

...see "Maintaining Moderna" ). The largest biotech IPO on NASDAQ belongs to plasma protein company Talecris Biotherapeutics Inc....
BioCentury | Nov 16, 2018
Financial News

At $500M, Moderna files to raise record IPO

...J.P. Morgan, BofA Merrill Lynch, Barclays, Piper Jaffray, Bryan Garnier, Oddo, Oppenheimer, Needham and Chardan. Talecris Biotherapeutics Inc....
...had multiple marketed therapies at the time of its listing; Grifols S.A. (Madrid:GRF; NASDAQ:GRFS) acquired Talecris...
BioCentury | Nov 10, 2018
Financial News

At $500M, Moderna files to raise record IPO

...J.P. Morgan, BofA Merrill Lynch, Barclays, Piper Jaffray, Bryan Garnier, Oddo, Oppenheimer, Needham and Chardan. Talecris Biotherapeutics Inc....
...had multiple marketed therapies at the time of its listing; Grifols S.A. (Madrid:GRF; NASDAQ:GRFS) acquired Talecris...
BioCentury | Mar 4, 2013
Finance

Analyst tracks

...Street Healthcare Partners, and Niles was CFO at HighPoint Capital. Perkins was an EVP at Talecris Biotherapeutics Inc....
BioCentury | Jun 25, 2012
Clinical News

Plasmin: Phase I data

...international Phase II trial for the indication. Grifols gained the product through its acquisition of Talecris Biotherapeutics Inc....
BioCentury | Dec 19, 2011
Company News

Zyngenia management update

...Autoimmune, Inflammation Hired: Daniel Menichella as CBO, formerly SVP of corporate development and strategy at Talecris Biotherapeutics Inc....
BioCentury | Jun 13, 2011
Company News

Grifols, Talecris deal

...plasma protein company Talecris in a cash and stock deal that the companies said values Talecris...
...at $26.16 per share, or about $3.4 billion. The price is a 64% premium to Talecris'...
...Grifols subsequently listed its American Depository Shares (ADS) on NASDAQ. Earlier this year, Grifols and Talecris...
Items per page:
1 - 10 of 114
BioCentury | Dec 14, 2018
Financial News

Moderna raises $604M in record IPO, loses $1.4B in trading debut

...held a 19.5% pre-IPO stake in the company. CEO Stéphane Bancel held 10%. Moderna knocks Talecris Biotherapeutics Inc....
...had multiple marketed therapies at the time of its listing. Grifols S.A. (Madrid:GRF; NASDAQ:GRFS) acquired Talecris...
BioCentury | Dec 7, 2018
Financial News

Moderna sets IPO record with upsized $604M offering

...held a 19.5% pre-IPO stake in the company. CEO Stéphane Bancel held 10%. Moderna knocks Talecris Biotherapeutics Inc....
...had multiple marketed therapies at the time of its listing. Grifols S.A. (Madrid:GRF; NASDAQ:GRFS) acquired Talecris...
BioCentury | Nov 30, 2018
Financial News

Moderna proposes terms for record IPO

...see "Maintaining Moderna" ). The largest biotech IPO on NASDAQ belongs to plasma protein company Talecris Biotherapeutics Inc....
BioCentury | Nov 28, 2018
Financial News

Moderna proposes terms for record IPO

...see "Maintaining Moderna" ). The largest biotech IPO on NASDAQ belongs to plasma protein company Talecris Biotherapeutics Inc....
BioCentury | Nov 16, 2018
Financial News

At $500M, Moderna files to raise record IPO

...J.P. Morgan, BofA Merrill Lynch, Barclays, Piper Jaffray, Bryan Garnier, Oddo, Oppenheimer, Needham and Chardan. Talecris Biotherapeutics Inc....
...had multiple marketed therapies at the time of its listing; Grifols S.A. (Madrid:GRF; NASDAQ:GRFS) acquired Talecris...
BioCentury | Nov 10, 2018
Financial News

At $500M, Moderna files to raise record IPO

...J.P. Morgan, BofA Merrill Lynch, Barclays, Piper Jaffray, Bryan Garnier, Oddo, Oppenheimer, Needham and Chardan. Talecris Biotherapeutics Inc....
...had multiple marketed therapies at the time of its listing; Grifols S.A. (Madrid:GRF; NASDAQ:GRFS) acquired Talecris...
BioCentury | Mar 4, 2013
Finance

Analyst tracks

...Street Healthcare Partners, and Niles was CFO at HighPoint Capital. Perkins was an EVP at Talecris Biotherapeutics Inc....
BioCentury | Jun 25, 2012
Clinical News

Plasmin: Phase I data

...international Phase II trial for the indication. Grifols gained the product through its acquisition of Talecris Biotherapeutics Inc....
BioCentury | Dec 19, 2011
Company News

Zyngenia management update

...Autoimmune, Inflammation Hired: Daniel Menichella as CBO, formerly SVP of corporate development and strategy at Talecris Biotherapeutics Inc....
BioCentury | Jun 13, 2011
Company News

Grifols, Talecris deal

...plasma protein company Talecris in a cash and stock deal that the companies said values Talecris...
...at $26.16 per share, or about $3.4 billion. The price is a 64% premium to Talecris'...
...Grifols subsequently listed its American Depository Shares (ADS) on NASDAQ. Earlier this year, Grifols and Talecris...
Items per page:
1 - 10 of 114